Serpins inhibit the toxicity of amyloid peptides
- PMID: 9153583
- DOI: 10.1111/j.1460-9568.1997.tb01425.x
Serpins inhibit the toxicity of amyloid peptides
Abstract
The amyloid plaque in Alzheimer's disease (AD) contains numerous proteins, some of which may be relevant to the pathogenesis of the disease. The serine protease inhibitor alpha1-antichymotrypsin is specifically localized in AD plaques. It is shown here that alpha1-antichymotrypsin and several other serine protease inhibitors (serpins) inhibit the toxicity of amyloid peptides on primary cortical nerve cell cultures as well as a clonal cell line. This inhibition of toxicity is not mediated via the serpin enzyme complex receptor, the transferrin receptor, or by interference with the polymerization of amyloid fibrils. Since a variety of synthetic serine protease inhibitors mimic the effects of serpins on amyloid toxicity, it is likely that the antiprotease activities of serpins are responsible for their biological effects.
Similar articles
-
Alpha 1-antichymotrypsin interaction with A beta (1-42) does not inhibit fibril formation but attenuates the peptide toxicity.Neurosci Lett. 1996 Oct 18;217(2-3):117-20. Neurosci Lett. 1996. PMID: 8916086
-
alpha-1-antichymotrypsin interaction with A beta (1-40) inhibits fibril formation but does not affect the peptide toxicity.Neurosci Lett. 1996 Jun 14;211(1):45-8. doi: 10.1016/0304-3940(96)12717-8. Neurosci Lett. 1996. PMID: 8809844
-
Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides.Neurobiol Aging. 1996 Sep-Oct;17(5):773-80. doi: 10.1016/0197-4580(96)00112-1. Neurobiol Aging. 1996. PMID: 8892351
-
The serpin solution; targeting thrombotic and thrombolytic serine proteases in inflammation.Cardiovasc Hematol Disord Drug Targets. 2013 Aug;13(2):99-110. doi: 10.2174/1871529x11313020003. Cardiovasc Hematol Disord Drug Targets. 2013. PMID: 23987998 Review.
-
Amyloid fibril toxicity in Alzheimer's disease and diabetes.Ann N Y Acad Sci. 1996 Jan 17;777:89-95. doi: 10.1111/j.1749-6632.1996.tb34406.x. Ann N Y Acad Sci. 1996. PMID: 8624132 Review.
Cited by
-
Patients with Alzheimer's disease have an increased removal rate of soluble beta-amyloid-42.PLoS One. 2022 Oct 31;17(10):e0276933. doi: 10.1371/journal.pone.0276933. eCollection 2022. PLoS One. 2022. PMID: 36315527 Free PMC article.
-
Amyloid beta peptide membrane perturbation is the basis for its biological effects.Neurochem Res. 1999 Dec;24(12):1621-30. doi: 10.1023/a:1021172620295. Neurochem Res. 1999. PMID: 10591414 Review.
-
Towards the Integrative Theory of Alzheimer's Disease: Linking Molecular Mechanisms of Neurotoxicity, Beta-amyloid Biomarkers, and the Diagnosis.Curr Alzheimer Res. 2023;20(6):440-452. doi: 10.2174/1567205020666230821141745. Curr Alzheimer Res. 2023. PMID: 37605411 Free PMC article.
-
Protease inhibitor coinfusion with amyloid beta-protein results in enhanced deposition and toxicity in rat brain.J Neurosci. 1998 Oct 15;18(20):8311-21. doi: 10.1523/JNEUROSCI.18-20-08311.1998. J Neurosci. 1998. PMID: 9763475 Free PMC article.
-
Per-6-substituted beta-cyclodextrin libraries inhibit formation of beta-amyloid-peptide (A beta)-derived, soluble oligomers.J Mol Neurosci. 2002 Aug-Oct;19(1-2):51-5. doi: 10.1007/s12031-002-0010-x. J Mol Neurosci. 2002. PMID: 12212793
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
